Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.

Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.

Myeloid and plasmacytoid dendritic cells (mDCs, pDCs) are central to the initiation and the regulation of immune processes in multiple sclerosis (MS). Natalizumab (NTZ) is a humanized monoclonal antibody approved for the treatment of MS that acts by blocking expression of VLA-4 integrins on the surf...

Full description

Bibliographic Details
Main Authors: Clara de Andrés, Roseta Teijeiro, Bárbara Alonso, Francisco Sánchez-Madrid, M Luisa Martínez, Juan Guzmán de Villoria, Eduardo Fernández-Cruz, Silvia Sánchez-Ramón
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22496780/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22496780/?tool=EBI

Similar Items